Cosmetic Composition and Method
A cosmetic topical formulation and method are directed toward diminishing skin wrinkling and fine lines and improving skin tone. It contains a matrix metalloproteinase inhibitor, MMPI, e.g. batimastat or marimastat, and a natural estrogen, e.g., a true estrogen compound, such as 17-beta estradiol, or an estrogen-like steroid (such as various phytoestrogens found in herbal preparations). Exemplary phytoestrogens include triterpenoid glycosides. Certain compositions of this invention are useful for minimizing photodamage to skin, while in other embodiments, a composition according to this invention is useful to prevent or minimize the adverse effects on skin induced by cigarette smoking. The method of the invention involves administering the components such as in a dermal preparation.
1 . A composition for preventing or reducing skin aging and wrinkling, which comprises at least one matrix metalloproteinase inhibitor (MMPI) and at least one estrogen or phytoestrogen, wherein said MMPI is selected from the group consisting of batimastat and marimastat.
2 . The composition of claim 1 further comprising an agent that acts as blocker of UVA and UVB radiation.
3 . The composition according to claim 1 wherein said estrogen or phytoestrogen is a plant extract, a purified phytoestrogen, a synthetic phytoestrogen, a natural estrogen, or a synthetic estrogen.
4 . The composition of claim 1 wherein the estrogen or phytoestrogen is a triterpenoid glycoside.
5 . The composition of claim 4 wherein the MMPI and triterpenoid glycoside are present in an amount effective to treat aging of skin.
6 . The composition of claim 4 wherein the MMPI and triterpenoid glycoside are present in an amount effective to treat photoaging of skin.
7 . The composition of claim 4 wherein the MMPI and triterpenoid glycoside are present in an amount effective to treat smoking induced wrinkling and fine lines in living human skin.
8 . A method for minimizing the adverse effects of aging on skin comprising contacting said skin with (a) batimastat or marimastat and (b) an estrogen or phytoestrogen.
9 . The method of claim 8 wherein said contacting is conducted at least once every twenty-four hours for the entire period during which said minimizing of the adverse effects of aging on skin is conducted.
10 . The method of claim 8 wherein said contacting is conducted prior to exposure to sunlight.
11 . The method of claim 8 wherein said contacting comprises administering said MMPI and estrogen or phytoestrogen in a dermal preparation.
12 . The method of claim 11 wherein said dermal preparation further comprises an agent that acts as blocker of UVA and UVB radiation.
13 . The method of claim 12 wherein said dermal preparation comprises about 40% by weight of water; up to about 35% by weight of a permeation enhancing compound selected from the group consisting of dibutyl adipate, isopropyl myristate and combinations thereof; up to about 15% by weight of a fatty alcohol; and one or more emollients or moisturizing humectants.